期刊
CLINICAL CANCER RESEARCH
卷 22, 期 1, 页码 69-78出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-15-1344
关键词
-
类别
资金
- NCI [5U24-CA076518]
- NHLBI [5U10HL069294]
- National Institute of Allergy and Infectious Diseases (NIAID)
- Health Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C]
- Office of Naval Research [N00014-13-1-0039, N00014-14-1-0028]
- Actinium Pharmaceuticals
- Allos Therapeutics, Inc.
- Amgen, Inc.
- Ariad
- Be the Match Foundation
- Blue Cross and Blue Shield Association
- Celgene Corporation
- Chimerix, Inc.
- Fred Hutchinson Cancer Research Center
- Fresenius-Biotech North America, Inc.
- Gamida Cell Teva Joint Venture Ltd.
- Genentech, Inc.
- Gentium SpA
- Genzyme Corporation
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Health Research, Inc. Roswell Park Cancer Institute
- HistoGenetics, Inc.
- Incyte Corporation
- Jeff Gordon Children's Foundation
- Kiadis Pharma
- The Leukemia & Lymphoma Society
- Medac GmbH
- Medical College of Wisconsin
- Merck Co, Inc.
- Mesoblast
- Millennium: The Takeda Oncology Co.
- Milliman USA, Inc.
- Miltenyi Biotec, Inc.
- National Marrow Donor Program
- Neovii Biotech NA, Inc.
- Novartis Pharmaceuticals Corporation
- Onyx Pharmaceuticals
- Optum Healthcare Solutions, Inc.
- Osiris Therapeutics, Inc.
- Otsuka America Pharmaceutical, Inc.
- Perkin Elmer, Inc.
- Remedy Informatics
- Sanofi US
- Seattle Genetics
- Sigma-Tau Pharmaceuticals
- Soligenix, Inc.
- Spectrum Pharmaceuticals, Inc.
- St. Baldrick's Foundation
- StemCyte, A Global Cord Blood Therapeutics Co.
- Stemsoft Software, Inc.
- Strakan, Inc.
- Sunesis Pharmaceuticals, Inc.
- Swedish Orphan Biovitrum
- Tarix Pharmaceuticals
- TerumoBCT
- Teva Neuroscience, Inc.
- THERAKOS, Inc.
- University of Minnesota
- Wellpoint, Inc.
- Medical College of Wisconsin Institutional Research Grant from American Cancer Society [86-004-26]
- USC/UCLA Center on Biodemography and Population Health [NIA P30 AG017265]
Purpose: Low socioeconomic status (SES) is associated with adverse outcomes among unrelated donor hematopoietic stem cell transplant (HCT) recipients, but the biologic mechanisms contributing to this health disparity are poorly understood. Therefore, we examined whether social environment affects expression of a stress-related gene expression profile known as the conserved transcriptional response to adversity (CTRA), which involves upregulation of proinflammatory genes and downregulation of genes involved in type I IFN response and antibody synthesis. Experimental Design: We compared pretransplant leukocyte CTRA gene expression between a group of 78 high versus low SES recipients of unrelated donor HCT for acute myelogenous leukemia in first remission. Post hoc exploratory analyses also evaluated whether CTRA gene expression was associated with poor clinical outcomes. Results: Peripheral blood mononuclear cells collected pre-HCT from low SES individuals demonstrated significant CTRA upregulation compared with matched HCT recipients of high SES. Promoter-based bioinformatics implicated distinct patterns of transcription factor activity, including increased CREB signaling and decreased IRF and GR signaling. High expression of the CTRA gene profile was also associated with increased relapse risk and decreased leukemia-free survival. Conclusions: Low SES is associated with increased expression of the CTRA gene profile, and CTRA gene expression is associated with adverse HCT clinical outcomes. These findings provide a biologic framework within which to understand how social environmental conditions may influence immune function and clinical outcomes in allogeneic HCT. (C)2015 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据